Fairmount Funds Management LLC - Sep 27, 2024 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Role
Director
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Stock symbol
DNTH
Transactions as of
Sep 27, 2024
Transactions value $
$0
Form type
4
Date filed
10/1/2024, 08:00 PM
Previous filing
Sep 17, 2024
Next filing
Nov 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNTH Common Stock Other $0 -62.1K -100% $0.00 0 Sep 27, 2024 By Fairmount SPV III, LLC F1, F2
holding DNTH Common Stock 2.7M Sep 27, 2024 By Fairmount Healthcare Fund II L.P. F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount SPV III, LLC ("Fairmount SPV") to its membership interest investors.
F2 Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II") and the Class A Member for Fairmount SPV. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Fairmount, Fund II and Fairmount SPV III, LLC may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.